000 04927naa a22006257i 4500
001 UMUN-OA-20261005-PH-058
003 local
005 20261005174916.0
006 m o d
007 cr||||||||||||
008 261005s2022 xx o u000 0 eng d
024 7 _a10.1016/j.eclinm.2022.101624
_2doi
035 _a(local)EuropePMC:PMC9417563
040 _alocal
_beng
_clocal
041 0 _aeng
100 0 _aKin Israel Notarte
_eauthor.
245 1 0 _aImpact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: A systematic review. /
_cKin Israel Notarte; Jesus Alfonso Catahay; Jacqueline Veronica Velasco [and others].
264 1 _a[Place of publication not identified] :
_bElsevier,
_c2022.
300 _a1 online resource (1 article).
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
500 _aThe source lists 13 contributors; the first 12 names are recorded as access points. The complete source author list is retained in the catalogue manifest.
500 _aPublication type: Journal article.
500 _aLinked open-access copy: published version.
506 0 _aOpen access; no subscription required for the linked open-access version.
_fUnrestricted online access
_2star
520 3 _aBackground Although COVID-19 vaccination decreases the risk of severe illness, it is unclear whether vaccine administration may impact the prevalence of long-COVID. The aim of this systematic review is to investigate the association between COVID-19 vaccination and long-COVID symptomatology. Methods MEDLINE, CINAHL, PubMed, EMBASE, and Web of Science databases, as well as medRxiv and bioRxiv preprint servers were searched up to June 20, 2022. Peer-reviewed studies or preprints monitoring multiple symptoms appearing after acute SARS-CoV-2 infection either before or after COVID-19 vaccination collected by personal, telephone or electronic interviews were included. The methodological quality of the studies was assessed using the Newcastle-Ottawa Scale. Findings From 2584 studies identified, 11 peer-reviewed studies and six preprints were included. The methodological quality of 82% ( n =14/17) studies was high. Six studies ( n =17,256,654 individuals) investigated the impact of vaccines before acute SARS-CoV-2 infection (vaccine-infection-long-COVID design). Overall, vaccination was associated with reduced risks or odds of long-COVID, with preliminary evidence suggesting that two doses are more effective than one dose. Eleven studies ( n =36,736 COVID-19 survivors) investigated changes in long-COVID symptoms after vaccination (infection-long-COVID-vaccine design). Seven articles showed an improvement in long-COVID symptoms at least one dose post-vaccination, while four studies reported no change or worsening in long-COVID symptoms after vaccination. Interpretation Low level of evidence (grade III, case-controls, cohort studies) suggests that vaccination before SARS-CoV-2 infection could reduce the risk of subsequent long-COVID. The impact of vaccination in people with existing long-COVID symptoms is still controversial, with some data showing changes in symptoms and others did not. These assumptions are limited to those vaccines used in the studies. Funding The LONG-COVID-EXP-CM study supported by a grant of Comunidad de Madrid.
540 _aCreative Commons Attribution (licence family recorded by the source; version not supplied in metadata).
_uhttps://europepmc.org/articles/PMC9417563
546 _aIn English.
588 0 _aDescription generated from Europe PMC bibliographic metadata retrieved on 5 October 2026; full text linked from the source.
590 _aCourse allocation: B. Sc. Public Health.
650 4 _aVaccine
650 4 _aSars-cov-2
650 4 _aPost-covid Syndrome
650 4 _aLong-covid Symptoms
653 _aB. Sc. Public Health
653 _aUMUN open access collection
653 _avaccination
655 4 _aJournal articles.
700 0 _aJesus Alfonso Catahay
_eauthor.
700 0 _aJacqueline Veronica Velasco
_eauthor.
700 0 _aAdriel Pastrana
_eauthor.
700 0 _aAbbygail Therese Ver
_eauthor.
700 0 _aFlos Carmeli Pangilinan
_eauthor.
700 0 _aPrincess Juneire Peligro
_eauthor.
700 0 _aMichael Casimiro
_eauthor.
700 0 _aJonathan Jaime Guerrero
_eauthor.
700 0 _aMa Margarita Leticia Gellaco
_eauthor.
700 0 _aGiuseppe Lippi
_eauthor.
700 0 _aBrandon Michael Henry
_eauthor.
773 0 _tEClinicalMedicine
_gVol. 53, (2022), pages/article 101624
_x2589-5370
856 4 0 _uhttps://europepmc.org/articles/PMC9417563
_yRead open-access publication
_zOpen access.
_70
884 _aCourse selection and automated MARC21 enrichment from Europe PMC metadata.
_g20261005
_khttps://europepmc.org/articles/PMC9417563
_qlocal
942 _n0
999 _c1330
_d1330